nodes	percent_of_prediction	percent_of_DWPC	metapath
Granisetron—CYP3A4—bone cancer	0.854	1	CbGaD
Granisetron—HTR3A—SIDS Susceptibility Pathways—FEV—bone cancer	0.000621	0.082	CbGpPWpGaD
Granisetron—Gastrointestinal haemorrhage—Epirubicin—bone cancer	0.000528	0.00382	CcSEcCtD
Granisetron—Anxiety—Cisplatin—bone cancer	0.000525	0.0038	CcSEcCtD
Granisetron—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000523	0.00378	CcSEcCtD
Granisetron—Liver function test abnormal—Methotrexate—bone cancer	0.000521	0.00376	CcSEcCtD
Granisetron—Discomfort—Cisplatin—bone cancer	0.000521	0.00376	CcSEcCtD
Granisetron—Migraine—Epirubicin—bone cancer	0.00052	0.00376	CcSEcCtD
Granisetron—Oedema—Cisplatin—bone cancer	0.000505	0.00365	CcSEcCtD
Granisetron—Anaphylactic shock—Cisplatin—bone cancer	0.000505	0.00365	CcSEcCtD
Granisetron—Infection—Cisplatin—bone cancer	0.000502	0.00363	CcSEcCtD
Granisetron—Nervous system disorder—Cisplatin—bone cancer	0.000495	0.00358	CcSEcCtD
Granisetron—Thrombocytopenia—Cisplatin—bone cancer	0.000495	0.00358	CcSEcCtD
Granisetron—Tachycardia—Cisplatin—bone cancer	0.000493	0.00356	CcSEcCtD
Granisetron—Skin disorder—Cisplatin—bone cancer	0.000491	0.00355	CcSEcCtD
Granisetron—Hyponatraemia—Doxorubicin—bone cancer	0.00049	0.00354	CcSEcCtD
Granisetron—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	0.000488	0.00353	CcSEcCtD
Granisetron—Hyperhidrosis—Cisplatin—bone cancer	0.000488	0.00353	CcSEcCtD
Granisetron—Liver function test abnormal—Epirubicin—bone cancer	0.000487	0.00352	CcSEcCtD
Granisetron—Eosinophilia—Methotrexate—bone cancer	0.000483	0.00349	CcSEcCtD
Granisetron—Orthostatic hypotension—Epirubicin—bone cancer	0.000482	0.00349	CcSEcCtD
Granisetron—Migraine—Doxorubicin—bone cancer	0.000481	0.00348	CcSEcCtD
Granisetron—Hypokalaemia—Epirubicin—bone cancer	0.00048	0.00347	CcSEcCtD
Granisetron—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000475	0.00344	CcSEcCtD
Granisetron—Hypotension—Cisplatin—bone cancer	0.000472	0.00341	CcSEcCtD
Granisetron—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000466	0.00337	CcSEcCtD
Granisetron—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00046	0.00333	CcSEcCtD
Granisetron—Abdominal distension—Epirubicin—bone cancer	0.000459	0.00332	CcSEcCtD
Granisetron—Dysuria—Methotrexate—bone cancer	0.000456	0.0033	CcSEcCtD
Granisetron—Paraesthesia—Cisplatin—bone cancer	0.000454	0.00328	CcSEcCtD
Granisetron—Eosinophilia—Epirubicin—bone cancer	0.000452	0.00327	CcSEcCtD
Granisetron—Liver function test abnormal—Doxorubicin—bone cancer	0.000451	0.00326	CcSEcCtD
Granisetron—Dyspnoea—Cisplatin—bone cancer	0.00045	0.00326	CcSEcCtD
Granisetron—Orthostatic hypotension—Doxorubicin—bone cancer	0.000446	0.00322	CcSEcCtD
Granisetron—Photosensitivity reaction—Methotrexate—bone cancer	0.000445	0.00322	CcSEcCtD
Granisetron—Hypokalaemia—Doxorubicin—bone cancer	0.000444	0.00321	CcSEcCtD
Granisetron—Angina pectoris—Epirubicin—bone cancer	0.000444	0.00321	CcSEcCtD
Granisetron—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.00044	0.00318	CcSEcCtD
Granisetron—Decreased appetite—Cisplatin—bone cancer	0.000439	0.00317	CcSEcCtD
Granisetron—Gastrointestinal disorder—Cisplatin—bone cancer	0.000436	0.00315	CcSEcCtD
Granisetron—Pain—Cisplatin—bone cancer	0.000432	0.00312	CcSEcCtD
Granisetron—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000431	0.00311	CcSEcCtD
Granisetron—Dysuria—Epirubicin—bone cancer	0.000427	0.00308	CcSEcCtD
Granisetron—Abdominal distension—Doxorubicin—bone cancer	0.000425	0.00307	CcSEcCtD
Granisetron—Eosinophilia—Doxorubicin—bone cancer	0.000418	0.00302	CcSEcCtD
Granisetron—Sweating—Methotrexate—bone cancer	0.000417	0.00301	CcSEcCtD
Granisetron—Photosensitivity reaction—Epirubicin—bone cancer	0.000416	0.00301	CcSEcCtD
Granisetron—Feeling abnormal—Cisplatin—bone cancer	0.000416	0.00301	CcSEcCtD
Granisetron—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000412	0.0544	CbGpPWpGaD
Granisetron—Angina pectoris—Doxorubicin—bone cancer	0.000411	0.00297	CcSEcCtD
Granisetron—Hepatobiliary disease—Methotrexate—bone cancer	0.000411	0.00297	CcSEcCtD
Granisetron—Epistaxis—Methotrexate—bone cancer	0.00041	0.00296	CcSEcCtD
Granisetron—Body temperature increased—Cisplatin—bone cancer	0.000399	0.00289	CcSEcCtD
Granisetron—Jaundice—Epirubicin—bone cancer	0.000396	0.00287	CcSEcCtD
Granisetron—Urinary tract infection—Epirubicin—bone cancer	0.000395	0.00286	CcSEcCtD
Granisetron—Dysuria—Doxorubicin—bone cancer	0.000395	0.00285	CcSEcCtD
Granisetron—Sweating—Epirubicin—bone cancer	0.00039	0.00282	CcSEcCtD
Granisetron—CYP1A1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00039	0.0514	CbGpPWpGaD
Granisetron—Photosensitivity reaction—Doxorubicin—bone cancer	0.000385	0.00279	CcSEcCtD
Granisetron—Hepatobiliary disease—Epirubicin—bone cancer	0.000385	0.00278	CcSEcCtD
Granisetron—Epistaxis—Epirubicin—bone cancer	0.000384	0.00277	CcSEcCtD
Granisetron—Sinusitis—Epirubicin—bone cancer	0.000382	0.00276	CcSEcCtD
Granisetron—Visual impairment—Methotrexate—bone cancer	0.000376	0.00272	CcSEcCtD
Granisetron—Hypersensitivity—Cisplatin—bone cancer	0.000372	0.00269	CcSEcCtD
Granisetron—Bradycardia—Epirubicin—bone cancer	0.000372	0.00269	CcSEcCtD
Granisetron—Jaundice—Doxorubicin—bone cancer	0.000367	0.00265	CcSEcCtD
Granisetron—Rhinitis—Epirubicin—bone cancer	0.000366	0.00265	CcSEcCtD
Granisetron—Urinary tract infection—Doxorubicin—bone cancer	0.000366	0.00264	CcSEcCtD
Granisetron—Asthenia—Cisplatin—bone cancer	0.000362	0.00262	CcSEcCtD
Granisetron—Sweating—Doxorubicin—bone cancer	0.000361	0.00261	CcSEcCtD
Granisetron—Connective tissue disorder—Epirubicin—bone cancer	0.000359	0.00259	CcSEcCtD
Granisetron—CYP1A1—Benzo(a)pyrene metabolism—CYP3A4—bone cancer	0.000356	0.047	CbGpPWpGaD
Granisetron—Hepatobiliary disease—Doxorubicin—bone cancer	0.000356	0.00257	CcSEcCtD
Granisetron—Epistaxis—Doxorubicin—bone cancer	0.000355	0.00257	CcSEcCtD
Granisetron—Angiopathy—Methotrexate—bone cancer	0.000354	0.00256	CcSEcCtD
Granisetron—Sinusitis—Doxorubicin—bone cancer	0.000353	0.00255	CcSEcCtD
Granisetron—Visual impairment—Epirubicin—bone cancer	0.000352	0.00254	CcSEcCtD
Granisetron—Chills—Methotrexate—bone cancer	0.00035	0.00253	CcSEcCtD
Granisetron—Diarrhoea—Cisplatin—bone cancer	0.000346	0.0025	CcSEcCtD
Granisetron—Alopecia—Methotrexate—bone cancer	0.000345	0.00249	CcSEcCtD
Granisetron—Bradycardia—Doxorubicin—bone cancer	0.000344	0.00249	CcSEcCtD
Granisetron—Malnutrition—Methotrexate—bone cancer	0.00034	0.00246	CcSEcCtD
Granisetron—Flushing—Epirubicin—bone cancer	0.000339	0.00245	CcSEcCtD
Granisetron—Rhinitis—Doxorubicin—bone cancer	0.000339	0.00245	CcSEcCtD
Granisetron—Dysgeusia—Methotrexate—bone cancer	0.000333	0.0024	CcSEcCtD
Granisetron—Connective tissue disorder—Doxorubicin—bone cancer	0.000332	0.0024	CcSEcCtD
Granisetron—Angiopathy—Epirubicin—bone cancer	0.000331	0.00239	CcSEcCtD
Granisetron—Chills—Epirubicin—bone cancer	0.000328	0.00237	CcSEcCtD
Granisetron—Arrhythmia—Epirubicin—bone cancer	0.000326	0.00236	CcSEcCtD
Granisetron—Visual impairment—Doxorubicin—bone cancer	0.000326	0.00235	CcSEcCtD
Granisetron—Alopecia—Epirubicin—bone cancer	0.000323	0.00233	CcSEcCtD
Granisetron—Vomiting—Cisplatin—bone cancer	0.000321	0.00232	CcSEcCtD
Granisetron—Rash—Cisplatin—bone cancer	0.000319	0.0023	CcSEcCtD
Granisetron—Dermatitis—Cisplatin—bone cancer	0.000318	0.0023	CcSEcCtD
Granisetron—Malnutrition—Epirubicin—bone cancer	0.000318	0.0023	CcSEcCtD
Granisetron—Ill-defined disorder—Methotrexate—bone cancer	0.000315	0.00228	CcSEcCtD
Granisetron—Anaemia—Methotrexate—bone cancer	0.000314	0.00227	CcSEcCtD
Granisetron—Flushing—Doxorubicin—bone cancer	0.000314	0.00227	CcSEcCtD
Granisetron—Flatulence—Epirubicin—bone cancer	0.000313	0.00226	CcSEcCtD
Granisetron—Tension—Epirubicin—bone cancer	0.000312	0.00225	CcSEcCtD
Granisetron—Dysgeusia—Epirubicin—bone cancer	0.000311	0.00225	CcSEcCtD
Granisetron—Nervousness—Epirubicin—bone cancer	0.000309	0.00223	CcSEcCtD
Granisetron—Angiopathy—Doxorubicin—bone cancer	0.000307	0.00222	CcSEcCtD
Granisetron—Malaise—Methotrexate—bone cancer	0.000306	0.00221	CcSEcCtD
Granisetron—Vertigo—Methotrexate—bone cancer	0.000305	0.00221	CcSEcCtD
Granisetron—Leukopenia—Methotrexate—bone cancer	0.000304	0.0022	CcSEcCtD
Granisetron—Chills—Doxorubicin—bone cancer	0.000303	0.00219	CcSEcCtD
Granisetron—Arrhythmia—Doxorubicin—bone cancer	0.000302	0.00218	CcSEcCtD
Granisetron—Nausea—Cisplatin—bone cancer	0.0003	0.00217	CcSEcCtD
Granisetron—Alopecia—Doxorubicin—bone cancer	0.000299	0.00216	CcSEcCtD
Granisetron—Cough—Methotrexate—bone cancer	0.000296	0.00214	CcSEcCtD
Granisetron—Ill-defined disorder—Epirubicin—bone cancer	0.000295	0.00213	CcSEcCtD
Granisetron—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000294	0.0389	CbGpPWpGaD
Granisetron—Malnutrition—Doxorubicin—bone cancer	0.000294	0.00213	CcSEcCtD
Granisetron—Anaemia—Epirubicin—bone cancer	0.000294	0.00212	CcSEcCtD
Granisetron—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000293	0.0387	CbGpPWpGaD
Granisetron—Agitation—Epirubicin—bone cancer	0.000292	0.00211	CcSEcCtD
Granisetron—Flatulence—Doxorubicin—bone cancer	0.00029	0.0021	CcSEcCtD
Granisetron—Chest pain—Methotrexate—bone cancer	0.000289	0.00209	CcSEcCtD
Granisetron—Arthralgia—Methotrexate—bone cancer	0.000289	0.00209	CcSEcCtD
Granisetron—Tension—Doxorubicin—bone cancer	0.000289	0.00209	CcSEcCtD
Granisetron—Dysgeusia—Doxorubicin—bone cancer	0.000288	0.00208	CcSEcCtD
Granisetron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000287	0.00208	CcSEcCtD
Granisetron—Malaise—Epirubicin—bone cancer	0.000287	0.00207	CcSEcCtD
Granisetron—Discomfort—Methotrexate—bone cancer	0.000286	0.00207	CcSEcCtD
Granisetron—Nervousness—Doxorubicin—bone cancer	0.000286	0.00207	CcSEcCtD
Granisetron—Vertigo—Epirubicin—bone cancer	0.000286	0.00206	CcSEcCtD
Granisetron—Syncope—Epirubicin—bone cancer	0.000285	0.00206	CcSEcCtD
Granisetron—Leukopenia—Epirubicin—bone cancer	0.000285	0.00206	CcSEcCtD
Granisetron—Palpitations—Epirubicin—bone cancer	0.000281	0.00203	CcSEcCtD
Granisetron—Loss of consciousness—Epirubicin—bone cancer	0.000279	0.00202	CcSEcCtD
Granisetron—Cough—Epirubicin—bone cancer	0.000277	0.00201	CcSEcCtD
Granisetron—Anaphylactic shock—Methotrexate—bone cancer	0.000277	0.002	CcSEcCtD
Granisetron—Infection—Methotrexate—bone cancer	0.000275	0.00199	CcSEcCtD
Granisetron—Hypertension—Epirubicin—bone cancer	0.000274	0.00198	CcSEcCtD
Granisetron—Ill-defined disorder—Doxorubicin—bone cancer	0.000273	0.00197	CcSEcCtD
Granisetron—Nervous system disorder—Methotrexate—bone cancer	0.000272	0.00197	CcSEcCtD
Granisetron—Anaemia—Doxorubicin—bone cancer	0.000272	0.00197	CcSEcCtD
Granisetron—Thrombocytopenia—Methotrexate—bone cancer	0.000271	0.00196	CcSEcCtD
Granisetron—Arthralgia—Epirubicin—bone cancer	0.000271	0.00196	CcSEcCtD
Granisetron—Chest pain—Epirubicin—bone cancer	0.000271	0.00196	CcSEcCtD
Granisetron—Agitation—Doxorubicin—bone cancer	0.00027	0.00195	CcSEcCtD
Granisetron—Anxiety—Epirubicin—bone cancer	0.00027	0.00195	CcSEcCtD
Granisetron—Skin disorder—Methotrexate—bone cancer	0.000269	0.00195	CcSEcCtD
Granisetron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000269	0.00194	CcSEcCtD
Granisetron—Hyperhidrosis—Methotrexate—bone cancer	0.000268	0.00194	CcSEcCtD
Granisetron—Discomfort—Epirubicin—bone cancer	0.000267	0.00193	CcSEcCtD
Granisetron—Malaise—Doxorubicin—bone cancer	0.000265	0.00192	CcSEcCtD
Granisetron—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.000265	0.0349	CbGpPWpGaD
Granisetron—Dry mouth—Epirubicin—bone cancer	0.000265	0.00191	CcSEcCtD
Granisetron—Vertigo—Doxorubicin—bone cancer	0.000264	0.00191	CcSEcCtD
Granisetron—Syncope—Doxorubicin—bone cancer	0.000264	0.00191	CcSEcCtD
Granisetron—Leukopenia—Doxorubicin—bone cancer	0.000263	0.0019	CcSEcCtD
Granisetron—Palpitations—Doxorubicin—bone cancer	0.00026	0.00188	CcSEcCtD
Granisetron—Anaphylactic shock—Epirubicin—bone cancer	0.000259	0.00188	CcSEcCtD
Granisetron—Oedema—Epirubicin—bone cancer	0.000259	0.00188	CcSEcCtD
Granisetron—Hypotension—Methotrexate—bone cancer	0.000259	0.00187	CcSEcCtD
Granisetron—Loss of consciousness—Doxorubicin—bone cancer	0.000258	0.00187	CcSEcCtD
Granisetron—Infection—Epirubicin—bone cancer	0.000258	0.00186	CcSEcCtD
Granisetron—Cough—Doxorubicin—bone cancer	0.000257	0.00186	CcSEcCtD
Granisetron—Shock—Epirubicin—bone cancer	0.000255	0.00185	CcSEcCtD
Granisetron—Nervous system disorder—Epirubicin—bone cancer	0.000254	0.00184	CcSEcCtD
Granisetron—Thrombocytopenia—Epirubicin—bone cancer	0.000254	0.00184	CcSEcCtD
Granisetron—Hypertension—Doxorubicin—bone cancer	0.000254	0.00184	CcSEcCtD
Granisetron—Tachycardia—Epirubicin—bone cancer	0.000253	0.00183	CcSEcCtD
Granisetron—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000253	0.00183	CcSEcCtD
Granisetron—Skin disorder—Epirubicin—bone cancer	0.000252	0.00182	CcSEcCtD
Granisetron—Hyperhidrosis—Epirubicin—bone cancer	0.000251	0.00181	CcSEcCtD
Granisetron—Insomnia—Methotrexate—bone cancer	0.000251	0.00181	CcSEcCtD
Granisetron—Arthralgia—Doxorubicin—bone cancer	0.00025	0.00181	CcSEcCtD
Granisetron—Chest pain—Doxorubicin—bone cancer	0.00025	0.00181	CcSEcCtD
Granisetron—Anxiety—Doxorubicin—bone cancer	0.00025	0.0018	CcSEcCtD
Granisetron—Paraesthesia—Methotrexate—bone cancer	0.000249	0.0018	CcSEcCtD
Granisetron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000249	0.0018	CcSEcCtD
Granisetron—Discomfort—Doxorubicin—bone cancer	0.000247	0.00179	CcSEcCtD
Granisetron—Dyspnoea—Methotrexate—bone cancer	0.000247	0.00179	CcSEcCtD
Granisetron—Somnolence—Methotrexate—bone cancer	0.000246	0.00178	CcSEcCtD
Granisetron—Dry mouth—Doxorubicin—bone cancer	0.000245	0.00177	CcSEcCtD
Granisetron—Dyspepsia—Methotrexate—bone cancer	0.000244	0.00176	CcSEcCtD
Granisetron—Hypotension—Epirubicin—bone cancer	0.000242	0.00175	CcSEcCtD
Granisetron—Decreased appetite—Methotrexate—bone cancer	0.000241	0.00174	CcSEcCtD
Granisetron—Anaphylactic shock—Doxorubicin—bone cancer	0.00024	0.00174	CcSEcCtD
Granisetron—Oedema—Doxorubicin—bone cancer	0.00024	0.00174	CcSEcCtD
Granisetron—Gastrointestinal disorder—Methotrexate—bone cancer	0.000239	0.00173	CcSEcCtD
Granisetron—Infection—Doxorubicin—bone cancer	0.000238	0.00172	CcSEcCtD
Granisetron—Pain—Methotrexate—bone cancer	0.000237	0.00171	CcSEcCtD
Granisetron—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000236	0.00171	CcSEcCtD
Granisetron—Shock—Doxorubicin—bone cancer	0.000236	0.00171	CcSEcCtD
Granisetron—Nervous system disorder—Doxorubicin—bone cancer	0.000235	0.0017	CcSEcCtD
Granisetron—Thrombocytopenia—Doxorubicin—bone cancer	0.000235	0.0017	CcSEcCtD
Granisetron—Insomnia—Epirubicin—bone cancer	0.000235	0.0017	CcSEcCtD
Granisetron—Tachycardia—Doxorubicin—bone cancer	0.000234	0.00169	CcSEcCtD
Granisetron—Skin disorder—Doxorubicin—bone cancer	0.000233	0.00169	CcSEcCtD
Granisetron—Paraesthesia—Epirubicin—bone cancer	0.000233	0.00168	CcSEcCtD
Granisetron—Hyperhidrosis—Doxorubicin—bone cancer	0.000232	0.00168	CcSEcCtD
Granisetron—Dyspnoea—Epirubicin—bone cancer	0.000231	0.00167	CcSEcCtD
Granisetron—Somnolence—Epirubicin—bone cancer	0.000231	0.00167	CcSEcCtD
Granisetron—Feeling abnormal—Methotrexate—bone cancer	0.000228	0.00165	CcSEcCtD
Granisetron—Dyspepsia—Epirubicin—bone cancer	0.000228	0.00165	CcSEcCtD
Granisetron—Gastrointestinal pain—Methotrexate—bone cancer	0.000227	0.00164	CcSEcCtD
Granisetron—Decreased appetite—Epirubicin—bone cancer	0.000226	0.00163	CcSEcCtD
Granisetron—CYP1A1—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000225	0.0297	CbGpPWpGaD
Granisetron—Hypotension—Doxorubicin—bone cancer	0.000224	0.00162	CcSEcCtD
Granisetron—Gastrointestinal disorder—Epirubicin—bone cancer	0.000224	0.00162	CcSEcCtD
Granisetron—Pain—Epirubicin—bone cancer	0.000222	0.0016	CcSEcCtD
Granisetron—Constipation—Epirubicin—bone cancer	0.000222	0.0016	CcSEcCtD
Granisetron—Urticaria—Methotrexate—bone cancer	0.00022	0.00159	CcSEcCtD
Granisetron—Abdominal pain—Methotrexate—bone cancer	0.000219	0.00158	CcSEcCtD
Granisetron—Body temperature increased—Methotrexate—bone cancer	0.000219	0.00158	CcSEcCtD
Granisetron—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000219	0.00158	CcSEcCtD
Granisetron—Insomnia—Doxorubicin—bone cancer	0.000217	0.00157	CcSEcCtD
Granisetron—Paraesthesia—Doxorubicin—bone cancer	0.000216	0.00156	CcSEcCtD
Granisetron—Dyspnoea—Doxorubicin—bone cancer	0.000214	0.00155	CcSEcCtD
Granisetron—Feeling abnormal—Epirubicin—bone cancer	0.000214	0.00155	CcSEcCtD
Granisetron—Somnolence—Doxorubicin—bone cancer	0.000213	0.00154	CcSEcCtD
Granisetron—Gastrointestinal pain—Epirubicin—bone cancer	0.000212	0.00153	CcSEcCtD
Granisetron—Dyspepsia—Doxorubicin—bone cancer	0.000211	0.00153	CcSEcCtD
Granisetron—Decreased appetite—Doxorubicin—bone cancer	0.000209	0.00151	CcSEcCtD
Granisetron—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000207	0.0274	CbGpPWpGaD
Granisetron—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000207	0.0015	CcSEcCtD
Granisetron—Urticaria—Epirubicin—bone cancer	0.000206	0.00149	CcSEcCtD
Granisetron—Pain—Doxorubicin—bone cancer	0.000205	0.00148	CcSEcCtD
Granisetron—Constipation—Doxorubicin—bone cancer	0.000205	0.00148	CcSEcCtD
Granisetron—Abdominal pain—Epirubicin—bone cancer	0.000205	0.00148	CcSEcCtD
Granisetron—Body temperature increased—Epirubicin—bone cancer	0.000205	0.00148	CcSEcCtD
Granisetron—CYP1A1—Estrogen metabolism—CYP3A4—bone cancer	0.000205	0.027	CbGpPWpGaD
Granisetron—Hypersensitivity—Methotrexate—bone cancer	0.000204	0.00148	CcSEcCtD
Granisetron—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000199	0.0263	CbGpPWpGaD
Granisetron—Asthenia—Methotrexate—bone cancer	0.000199	0.00144	CcSEcCtD
Granisetron—Feeling abnormal—Doxorubicin—bone cancer	0.000198	0.00143	CcSEcCtD
Granisetron—Gastrointestinal pain—Doxorubicin—bone cancer	0.000196	0.00142	CcSEcCtD
Granisetron—Pruritus—Methotrexate—bone cancer	0.000196	0.00142	CcSEcCtD
Granisetron—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000192	0.0253	CbGpPWpGaD
Granisetron—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000191	0.0252	CbGpPWpGaD
Granisetron—Hypersensitivity—Epirubicin—bone cancer	0.000191	0.00138	CcSEcCtD
Granisetron—Urticaria—Doxorubicin—bone cancer	0.000191	0.00138	CcSEcCtD
Granisetron—Body temperature increased—Doxorubicin—bone cancer	0.00019	0.00137	CcSEcCtD
Granisetron—Abdominal pain—Doxorubicin—bone cancer	0.00019	0.00137	CcSEcCtD
Granisetron—Diarrhoea—Methotrexate—bone cancer	0.00019	0.00137	CcSEcCtD
Granisetron—CYP1A1—Xenobiotics—CYP3A4—bone cancer	0.000188	0.0248	CbGpPWpGaD
Granisetron—Asthenia—Epirubicin—bone cancer	0.000186	0.00135	CcSEcCtD
Granisetron—Pruritus—Epirubicin—bone cancer	0.000184	0.00133	CcSEcCtD
Granisetron—Dizziness—Methotrexate—bone cancer	0.000183	0.00133	CcSEcCtD
Granisetron—CYP1A1—Tamoxifen metabolism—CYP3A4—bone cancer	0.000181	0.0239	CbGpPWpGaD
Granisetron—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00018	0.0238	CbGpPWpGaD
Granisetron—Diarrhoea—Epirubicin—bone cancer	0.000177	0.00128	CcSEcCtD
Granisetron—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000177	0.0234	CbGpPWpGaD
Granisetron—Hypersensitivity—Doxorubicin—bone cancer	0.000177	0.00128	CcSEcCtD
Granisetron—Vomiting—Methotrexate—bone cancer	0.000176	0.00127	CcSEcCtD
Granisetron—Rash—Methotrexate—bone cancer	0.000175	0.00126	CcSEcCtD
Granisetron—Dermatitis—Methotrexate—bone cancer	0.000175	0.00126	CcSEcCtD
Granisetron—Headache—Methotrexate—bone cancer	0.000174	0.00126	CcSEcCtD
Granisetron—Asthenia—Doxorubicin—bone cancer	0.000172	0.00125	CcSEcCtD
Granisetron—Dizziness—Epirubicin—bone cancer	0.000172	0.00124	CcSEcCtD
Granisetron—Pruritus—Doxorubicin—bone cancer	0.00017	0.00123	CcSEcCtD
Granisetron—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000169	0.0223	CbGpPWpGaD
Granisetron—CYP1A1—Metapathway biotransformation—CYP4V2—bone cancer	0.000168	0.0221	CbGpPWpGaD
Granisetron—Vomiting—Epirubicin—bone cancer	0.000165	0.00119	CcSEcCtD
Granisetron—Nausea—Methotrexate—bone cancer	0.000165	0.00119	CcSEcCtD
Granisetron—Diarrhoea—Doxorubicin—bone cancer	0.000164	0.00119	CcSEcCtD
Granisetron—Rash—Epirubicin—bone cancer	0.000164	0.00118	CcSEcCtD
Granisetron—Dermatitis—Epirubicin—bone cancer	0.000163	0.00118	CcSEcCtD
Granisetron—Headache—Epirubicin—bone cancer	0.000163	0.00117	CcSEcCtD
Granisetron—Dizziness—Doxorubicin—bone cancer	0.000159	0.00115	CcSEcCtD
Granisetron—Nausea—Epirubicin—bone cancer	0.000154	0.00111	CcSEcCtD
Granisetron—Vomiting—Doxorubicin—bone cancer	0.000153	0.0011	CcSEcCtD
Granisetron—Rash—Doxorubicin—bone cancer	0.000151	0.00109	CcSEcCtD
Granisetron—Dermatitis—Doxorubicin—bone cancer	0.000151	0.00109	CcSEcCtD
Granisetron—Headache—Doxorubicin—bone cancer	0.00015	0.00109	CcSEcCtD
Granisetron—Nausea—Doxorubicin—bone cancer	0.000143	0.00103	CcSEcCtD
Granisetron—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000141	0.0187	CbGpPWpGaD
Granisetron—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000137	0.018	CbGpPWpGaD
Granisetron—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000136	0.018	CbGpPWpGaD
Granisetron—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000126	0.0166	CbGpPWpGaD
Granisetron—CYP1A1—Estrogen Receptor Pathway—JUN—bone cancer	0.000106	0.014	CbGpPWpGaD
Granisetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000104	0.0137	CbGpPWpGaD
Granisetron—CYP1A1—Tryptophan metabolism—CYP3A4—bone cancer	9.65e-05	0.0127	CbGpPWpGaD
Granisetron—HTR3A—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.71e-05	0.0115	CbGpPWpGaD
Granisetron—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	8.26e-05	0.0109	CbGpPWpGaD
Granisetron—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	8.25e-05	0.0109	CbGpPWpGaD
Granisetron—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	8.15e-05	0.0108	CbGpPWpGaD
Granisetron—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	7.81e-05	0.0103	CbGpPWpGaD
Granisetron—CYP1A1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	7.7e-05	0.0102	CbGpPWpGaD
Granisetron—HTR3A—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.52e-05	0.00992	CbGpPWpGaD
Granisetron—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	6.7e-05	0.00884	CbGpPWpGaD
Granisetron—CYP1A1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	6.33e-05	0.00835	CbGpPWpGaD
Granisetron—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	5.87e-05	0.00775	CbGpPWpGaD
Granisetron—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	5.8e-05	0.00765	CbGpPWpGaD
Granisetron—CYP1A1—Aryl Hydrocarbon Receptor—RB1—bone cancer	5.2e-05	0.00687	CbGpPWpGaD
Granisetron—HTR3A—SIDS Susceptibility Pathways—JUN—bone cancer	4.91e-05	0.00648	CbGpPWpGaD
Granisetron—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	4.76e-05	0.00628	CbGpPWpGaD
Granisetron—CYP1A1—Tryptophan metabolism—MDM2—bone cancer	4.44e-05	0.00586	CbGpPWpGaD
Granisetron—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	4.28e-05	0.00564	CbGpPWpGaD
Granisetron—CYP1A1—Arachidonic acid metabolism—PTGS2—bone cancer	4e-05	0.00528	CbGpPWpGaD
Granisetron—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	3.86e-05	0.00509	CbGpPWpGaD
Granisetron—CYP3A5—Biological oxidations—CYP3A4—bone cancer	3.56e-05	0.00469	CbGpPWpGaD
Granisetron—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	3.51e-05	0.00463	CbGpPWpGaD
Granisetron—CYP1A1—Biological oxidations—CYP3A4—bone cancer	3.36e-05	0.00444	CbGpPWpGaD
Granisetron—CYP1A1—Metapathway biotransformation—CYP3A4—bone cancer	3.32e-05	0.00437	CbGpPWpGaD
Granisetron—CYP3A5—Biological oxidations—GSTP1—bone cancer	3.04e-05	0.00402	CbGpPWpGaD
Granisetron—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	3.03e-05	0.004	CbGpPWpGaD
Granisetron—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	3.03e-05	0.004	CbGpPWpGaD
Granisetron—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	3e-05	0.00396	CbGpPWpGaD
Granisetron—CYP1A1—Biological oxidations—GSTP1—bone cancer	2.87e-05	0.00379	CbGpPWpGaD
Granisetron—CYP1A1—Metapathway biotransformation—GSTP1—bone cancer	2.84e-05	0.00374	CbGpPWpGaD
Granisetron—CYP2D6—Biological oxidations—CYP3A4—bone cancer	2.53e-05	0.00334	CbGpPWpGaD
Granisetron—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	2.5e-05	0.00329	CbGpPWpGaD
Granisetron—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	2.18e-05	0.00288	CbGpPWpGaD
Granisetron—CYP2D6—Biological oxidations—GSTP1—bone cancer	2.16e-05	0.00286	CbGpPWpGaD
Granisetron—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	2.13e-05	0.00282	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—NDUFA12—bone cancer	2.13e-05	0.00281	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—NDUFA12—bone cancer	2.01e-05	0.00266	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—NT5C3A—bone cancer	1.77e-05	0.00233	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—NT5C3A—bone cancer	1.67e-05	0.0022	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—NDUFA12—bone cancer	1.52e-05	0.002	CbGpPWpGaD
Granisetron—CYP3A4—Biological oxidations—GSTP1—bone cancer	1.41e-05	0.00187	CbGpPWpGaD
Granisetron—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	1.4e-05	0.00184	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—NT5C3A—bone cancer	1.26e-05	0.00166	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—NDUFA12—bone cancer	9.91e-06	0.00131	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—NT5C3A—bone cancer	8.22e-06	0.00108	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—ENO2—bone cancer	7.74e-06	0.00102	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—ENO2—bone cancer	7.31e-06	0.000965	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—DHFR—bone cancer	7.18e-06	0.000948	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—DHFR—bone cancer	6.78e-06	0.000895	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—GNA11—bone cancer	6.71e-06	0.000886	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—GNA11—bone cancer	6.34e-06	0.000837	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—CYP3A4—bone cancer	6.08e-06	0.000803	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—CYP3A4—bone cancer	5.75e-06	0.000759	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.72e-06	0.000755	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—ENO2—bone cancer	5.5e-06	0.000726	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—GSTP1—bone cancer	5.2e-06	0.000687	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—DHFR—bone cancer	5.11e-06	0.000674	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—GSTP1—bone cancer	4.92e-06	0.000649	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—GNA11—bone cancer	4.77e-06	0.00063	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—CYP3A4—bone cancer	4.33e-06	0.000571	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—GSTP1—bone cancer	3.7e-06	0.000488	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—ENO2—bone cancer	3.6e-06	0.000475	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—DHFR—bone cancer	3.34e-06	0.000441	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—GNA11—bone cancer	3.12e-06	0.000412	CbGpPWpGaD
Granisetron—CYP3A5—Metabolism—PTGS2—bone cancer	2.7e-06	0.000356	CbGpPWpGaD
Granisetron—CYP1A1—Metabolism—PTGS2—bone cancer	2.55e-06	0.000336	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—GSTP1—bone cancer	2.42e-06	0.000319	CbGpPWpGaD
Granisetron—CYP2D6—Metabolism—PTGS2—bone cancer	1.92e-06	0.000253	CbGpPWpGaD
Granisetron—CYP3A4—Metabolism—PTGS2—bone cancer	1.25e-06	0.000165	CbGpPWpGaD
